

Supplementary Documents [IFRS]

Financial results for the first nine months of the fiscal year 2015 (FY2015)

Astellas Pharma Inc.

- 3Q/FY2015 Financial Results
 - Nine months ended December 31, 2015
 - Three months ended December 31, 2015
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties.

Actual financial results may differ materially depending on a number of factors including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new products effectively, interruptions in production, infringements of the company's intellectual property rights and the adverse outcome of material litigation.

This material contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations, promote unapproved uses in any fashion nor provide medical advice of any kind.

[Nine months ended December 31, 2015]

1. Consolidated Results (Full Basis)

	Unit: B¥				FY14 Full Year	Forecasts	
	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)		FY15 Full Year	Change from FY14 (%)
Sales	952.8	1,065.7	112.9	11.8%	1,247.3	1,384.0	11.0%
Cost of sales	259.5	270.5	11.0	4.2%	333.2		
Ratio to Sales	27.2%	25.4%			26.7%		
Gross profit	693.3	795.2	101.9	14.7%	914.1		
SG&A expenses	317.2	362.7	45.5	14.3%	452.5		
Ratio to Sales	33.3%	34.0%			36.3%		
Advertising and Sales Promotion	93.2	125.1	31.9	34.2%	138.5		
Personnel expenses	129.8	137.3	7.5	5.8%	178.1		
Other	94.3	100.4	6.1	6.4%	136.0		
R&D expenses	148.0	165.0	17.0	11.5%	206.6	238.0	15.2%
Ratio to Sales	15.5%	15.5%			16.6%	17.2%	
Amortisation of intangible assets	28.0	33.2	5.1	18.3%	38.7		
Share of profits/losses of associates and joint ventures	0.1	-0.5	-0.6	-	0.2		
Other income	4.1	1.1	-3.0	-73.3%	12.5		
Gain on sales of property, plant and equipment	1.4	0.3	-1.1	-76.5%	1.4		
Other expense	42.6	19.4	-23.3	-54.6%	43.3		
Loss on sales and disposal of property, plant and equipment	0.7	0.5	-0.2	-31.7%	1.2		
Impairment losses	9.1	9.5	0.4	4.1%	10.3		
Restructuring costs	11.5	-	-11.5	-	11.5		
Net foreign exchange losses	10.0	7.0	-3.0	-29.9%	3.6		
Litigation costs	11.0	2.1	-8.8	-80.5%	16.2		
Operating profit	161.7	215.6	53.9	33.3%	185.7	229.0	23.3%
Ratio to Sales	17.0%	20.2%			14.9%	16.5%	
Finance income	2.9	13.8	10.9	380.9%	7.1		
Gain on sales of available-for-sale financial assets	1.1	12.1	11.0	-	5.1		
Finance expense	2.9	0.9	-2.0	-68.1%	3.1		
Impairment losses for available-for-sale financial assets	2.6	0.1	-2.5	-95.0%	2.6		
Profit before tax	161.6	228.5	66.8	41.4%	189.7	242.0	27.6%
Ratio to Sales	17.0%	21.4%			15.2%	17.5%	
Income tax expense	46.9	63.9	17.0	36.4%	53.8		
Profit for the period	114.7	164.5	49.8	43.4%	135.9	172.0	26.6%
Ratio to Sales	12.0%	15.4%			10.9%	12.4%	
Comprehensive income	197.6	166.5	-31.1	-15.7%	169.5		

2. Consolidated Results (Core Basis)	Unit: B¥				FY14 Full Year	Forecasts Change from FY14	
	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)		FY15 Full Year	Change (%)
Sales	952.8	1,065.7	112.9	11.8%	1,247.3	1,384.0	11.0%
Cost of sales	259.5	270.5	11.0	4.2%	333.2		
	Ratio to Sales	27.2%	25.4%		26.7%		
Gross profit	693.3	795.2	101.9	14.7%	914.1		
SG&A expenses	317.2	362.7	45.5	14.3%	452.5		
	Ratio to Sales	33.3%	34.0%		36.3%		
Advertising and Sales Promotion	93.2	125.1	31.9	34.2%	138.5		
Personnel expenses	129.8	137.3	7.5	5.8%	178.1		
Other	94.3	100.4	6.1	6.4%	136.0		
R&D expenses	148.0	165.0	17.0	11.5%	206.6	238.0	15.2%
	Ratio to Sales	15.5%	15.5%		16.6%	17.2%	
Amortisation of intangible assets	28.0	33.2	5.1	18.3%	38.7		
Share of profits/losses of associates and joint ventures	0.1	-0.5	-0.6	-	0.2		
Operating profit	200.2	233.9	33.7	16.8%	216.5	244.0	12.7%
	Ratio to Sales	21.0%	21.9%		17.4%	17.6%	
Finance income	1.8	1.7	-0.0	-1.7%	1.9		
Finance expense	0.3	0.6	0.3	92.8%	0.4		
Profit before Tax	201.7	235.1	33.4	16.5%	218.1		
	Ratio to Sales	21.2%	22.1%		17.5%		
Income tax expense	61.4	65.7	4.3	7.0%	64.8		
Profit for the period	140.3	169.4	29.1	20.7%	153.2	175.0	14.2%
	Ratio to Sales	14.7%	15.9%		12.3%	12.6%	

3. Exchange Rate

	Unit: yen				FY14 Full Year	Forecasts	
	FY14 APR. - DEC.Ave.	FY15 APR. - DEC.Ave.	FY14 End	FY15 3Q End		FY14 Full Year	FY15 Full Year
USD/Yen	107	122	120	121	110	121	
EUR/Yen	140	134	130	132	139	133	

* Exchange rate fluctuations had positive impact by 36.2 billion yen on sales and positive impact by 15.4 billion yen on Core operating profit in Q3/FY2015

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY14 APR. - DEC.			FY15 APR. - DEC.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	952.8	-	952.8	1,065.7	-	1,065.7
Cost of sales	259.5	-	259.5	270.5	-	270.5
Gross profit	693.3	-	693.3	795.2	-	795.2
SG&A expenses	317.2	-	317.2	362.7	-	362.7
R&D expenses	148.0	-	148.0	165.0	-	165.0
Amortisation of intangible assets	28.0	-	28.0	33.2	-	33.2
Share of profits/losses of associates and joint ventures	0.1	-	0.1	-0.5	-	-0.5
Other income *1	4.1	-4.1	-	1.1	-1.1	-
Other expense *1	42.6	-42.6	-	19.4	-19.4	-
Operating profit	161.7	38.5	200.2	215.6	18.3	233.9
Finance income *2	2.9	-1.1	1.8	13.8	-12.1	1.7
Finance expense *2	2.9	-2.6	0.3	0.9	-0.4	0.6
Profit before tax	161.6	40.1	201.7	228.5	6.6	235.1
Income tax expense	46.9	14.5	61.4	63.9	1.8	65.7
Profit for the period	114.7	25.5	140.3	164.5	4.8	169.4

*1. "Other income" and "Other expense" are excluded from Core results.

"Other income" and "Other expense" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, loss on the restructuring, litigation costs and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale ("AFS") and impairment losses of AFS included in "Finance income" and "Finance expense" are excluded from Core results as non-core items.

5. Segment Information by Region

Unit: B¥

		FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)
Sales		952.8	1,065.7	112.9	11.8%
Japan		388.6	396.8	8.2	2.1%
	Ratio to Sales	40.8%	37.2%		
Americas		268.3	348.7	80.4	30.0%
	Ratio to Sales	28.2%	32.7%		
EMEA		243.3	251.4	8.1	3.3%
	Ratio to Sales	25.5%	23.6%		
Asia and Oceania		52.5	68.8	16.3	31.0%
	Ratio to Sales	5.5%	6.5%		

FY14 Full Year
1,247.3
498.7
361.0
28.9%
313.3
74.2
5.9%

Forecasts		Change from FY14
FY15 Full Year	Change (%)	
1,384.0	11.0%	
504.4	1.2%	
36.4%		
452.1	25.2%	
32.7%		
335.0	6.9%	
24.2%		
92.5	24.6%	
6.7%		

- Calculated according to locations of sellers.

- EMEA: Europe, Middle East and Africa

6. Addition to Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

		FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)
Depreciation (PP&E)					
	Consolidated	16.0	15.5	-0.5	-3.1%
Amortisation (Intangible Assets) *					
	Consolidated	32.1	37.6	5.4	17.0%

FY14 Full Year
21.3
44.2

Forecasts		Change from FY14
FY15 Full Year	Change (%)	
22.5	5.5%	
50.0	13.2%	

* Amortisation (Intangible Assets): Including amortisation of software, etc.

7. Sales of major products

1) Sales of global products

Unit: B¥

	Unit: B¥				FY14 Full Year	Forecasts	
	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)		FY15 Full Year	Change FY14 (%)
XTANDI	94.9	188.8	93.8	98.8%	137.2	253.3	84.6%
US	59.4	112.9	53.5	90.1%	85.7	147.6	72.2%
ex-US	35.6	75.9	40.3	113.4%	51.5	105.8	105.3%
Japan	10.2	20.2	10.0	98.3%	14.9	28.0	88.4%
Americas (ex-US)	1.9	3.4	1.4	74.3%	2.6	4.3	65.2%
EMEA	23.1	50.7	27.5	118.9%	33.4	71.1	112.8%
Asia and Oceania	0.3	1.7	1.4	425.5%	0.6	2.3	280.8%
Eligard	14.6	13.7	-0.9	-6.3%	19.0	18.2	-4.3%
EMEA	14.6	13.5	-1.0	-7.1%	18.9	18.0	-5.1%
Asia and Oceania	0.0	0.2	0.1	370.6%	0.1	0.2	219.8%
Vesicare	104.2	104.8	0.7	0.6%	135.2	133.4	-1.3%
Japan	19.3	20.6	1.3	6.7%	25.6	27.0	5.5%
Americas	47.8	49.0	1.2	2.6%	61.4	62.4	1.5%
EMEA	32.9	30.9	-2.0	-6.0%	42.3	38.2	-9.7%
Asia and Oceania	3.8	4.0	0.3	7.4%	5.3	5.6	5.1%
Betanis/Myrbetriq/Betmiga	37.8	60.1	22.3	59.1%	53.1	81.9	54.0%
Japan	10.5	15.8	5.2	49.6%	14.8	22.1	49.2%
Americas	19.9	33.4	13.5	67.8%	27.9	44.3	59.0%
EMEA	7.2	10.1	2.9	40.4%	10.3	14.6	41.7%
Asia and Oceania	0.1	0.8	0.7	680.5%	0.2	0.9	420.0%
Harnal/Omnic	42.9	41.8	-1.1	-2.6%	56.0	56.0	0.0%
Sales by Astellas	40.2	39.3	-0.9	-2.2%	51.9	52.0	0.1%
Japan	11.8	10.1	-1.6	-13.9%	15.0	12.8	-14.4%
EMEA	14.8	12.3	-2.5	-17.0%	18.0	16.7	-7.0%
Asia and Oceania	13.2	16.3	3.1	23.8%	18.3	21.8	19.3%
Bulk and Royalties	2.7	2.5	-0.2	-8.5%	4.1	4.0	-2.0%
Prograf	147.8	157.5	9.7	6.5%	194.7	202.5	4.0%
Sales by Astellas	145.3	155.2	9.9	6.8%	190.9	199.8	4.7%
Japan (Including Graceptor)	37.3	39.0	1.8	4.7%	48.1	50.7	5.3%
Americas	25.6	26.9	1.3	5.2%	33.0	33.3	0.7%
EMEA	59.4	60.2	0.8	1.3%	77.7	77.3	-0.5%
Advagraf	21.7	23.9	2.2	10.0%	28.7		
Asia and Oceania	23.0	29.0	6.0	26.1%	32.0	38.5	20.6%
Exports to third parties	2.5	2.3	-0.2	-8.8%	3.8	2.7	-30.6%
Funguard/Mycamine	29.8	32.0	2.1	7.1%	38.8	42.4	9.3%
Japan	9.3	9.3	-0.1	-0.8%	11.8	12.1	3.0%
Americas	9.2	10.0	0.8	8.9%	12.4	12.9	4.7%
EMEA	8.2	8.5	0.3	3.2%	10.2	11.7	14.1%
Asia and Oceania	3.1	4.2	1.1	35.6%	4.4	5.6	28.2%
Protopic	18.0	12.1	-5.9	-32.9%	21.7	14.9	-31.2%
Americas	9.7	2.8	-6.8	-70.6%	10.3	2.9	-71.7%
EMEA	5.7	5.6	-0.1	-2.0%	7.8	7.0	-10.3%
Asia and Oceania	2.5	3.4	0.9	37.4%	3.4	4.8	39.6%

- Sales of products in Japan are shown in a gross sales basis.

- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)
<Global products>				
XTANDI	10.2	20.2	10.0	98.3%
Vesicare	19.3	20.6	1.3	6.7%
Betanis	10.5	15.8	5.2	49.6%
Harnal	11.8	10.1	-1.6	-13.9%
Prograf (Including Graceptor)	37.3	39.0	1.8	4.7%
Funguard	9.3	9.3	-0.1	-0.8%
<Local products in Japan>				
Micardis [Family]	75.1	76.9	1.8	2.5%
Micombi	8.4	8.0	-0.4	-4.7%
Micamlo	18.4	20.3	1.9	10.5%
Celecox	31.6	36.2	4.5	14.3%
Symbicort	25.0	28.9	3.9	15.5%
Bonoteo	9.8	11.0	1.2	12.4%
Geninax	8.1	8.6	0.5	5.6%
Vaccines	33.5	38.6	5.1	15.2%
Argamate	4.6	4.8	0.2	4.5%
Kiklin	1.2	1.2	0.1	8.0%
Gonax	2.6	3.0	0.4	14.8%
Cimzia	3.8	5.0	1.2	32.2%
Suglat	3.3	5.5	2.2	67.3%
Lipitor*	29.0	24.8	-4.3	-14.8%
Myslee	15.1	14.2	-0.9	-5.8%
Gaster	14.2	11.8	-2.5	-17.3%
Seroquel	10.0	8.5	-1.5	-15.4%
Total Rx Sales In Japanese market	375.3	386.1	10.8	2.9%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015. Sales in FY2014 exclude sales of Caduet.

	Change from FY14	
	Forecasts	
	FY15 Full Year	Change (%)
	14.9	88.4%
	25.6	5.5%
	14.8	49.2%
	15.0	-14.4%
	48.1	5.3%
	11.8	3.0%
	95.7	2.9%
	10.7	
	23.8	
	41.8	12.4%
	33.0	12.2%
	13.0	11.5%
	10.4	2.7%
	38.8	3.1%
	5.9	3.6%
	1.5	12.1%
	3.4	17.7%
	5.0	34.0%
	4.1	102.6%
	36.7	-17.0%
	19.4	-9.1%
	18.0	-17.8%
	12.6	-15.1%
	481.7	1.7%

3) Sales of products in Americas and EMEA

Unit: B¥

	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)
Scan* (Americas)	49.3	58.8	9.5	19.2%
Lexiscan	49.1	58.6	9.5	19.4%
AmBisome (Americas)	6.6	8.2	1.7	25.7%
Tarceva	37.0	37.3	0.3	0.9%
(US)	25.3	27.1	1.8	7.2%
(ex-US)	11.6	10.1	-1.5	-12.8%
Qutenza (EMEA)	1.4	1.6	0.2	12.9%
DIFICLIR (EMEA)	1.5	2.0	0.5	32.3%

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

	Change from FY14	
	Forecasts	
	FY15 Full Year	Change (%)
	66.3	17.3%
	65.9	
	9.0	15.7%
	48.9	
	33.5	
	15.3	
	1.9	
	2.0	

4) Sales in Americas and EMEA (Local currency)

Unit: M\$

Americas	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)
Sales	2,511	2,865	355	14.1%
XTANDI	573	955	382	66.5%
US	555	927	372	67.0%
Americas (ex-US)	18	28	10	53.1%
Tarceva	346	306	-39	-11.4%
US	237	223	-14	-5.9%
ex-US	109	83	-26	-23.4%
VESIcare	447	403	-44	-9.9%
Myrbetriq	186	275	88	47.4%
Prograf	240	221	-18	-7.7%
Scan*	461	483	22	4.7%
Lexiscan	459	482	22	4.9%
MYCAMINE	86	82	-4	-4.4%
AmBisome	61	68	6	10.4%
CRESEMBA	-	14	14	-
Protopic	90	23	-67	-74.2%

* Adenoscan + Lexiscan

FY14 Full Year	Forecasts	
	FY15 Full Year	Change from FY14 (%)
3,284	3,739	13.9%
803	1,256	56.4%
779	1,220	56.6%
24	36	50.2%
444		
305		
139		
559	516	-7.7%
254	367	44.6%
301	275	-8.4%
603	643	6.7%
112	107	-4.8%
82	86	5.2%
-		
94	24	-74.2%

Unit: M€

EMEA	FY14 APR. - DEC.	FY15 APR. - DEC.	Change	Change (%)
Sales	1,734	1,871	137	7.9%
XTANDI	165	377	212	128.6%
Eligard	104	101	-3	-3.0%
Vesicare	234	230	-4	-1.8%
BETMIGA	51	75	24	46.6%
Omnice	125	110	-15	-11.9%
Sales by Astellas	106	91	-14	-13.3%
Capsule	53	45	-8	-15.0%
OCAS	53	46	-6	-11.7%
Bulk and Royalties	20	19	-1	-4.4%
Prograf	442	465	24	5.4%
Sales by Astellas	423	448	25	5.8%
Advagraf	155	178	23	14.9%
Exports to third parties	18	17	-1	-4.7%
MYCAMINE	58	63	5	7.7%
Protopic	41	42	1	2.3%
Qutenza	10	12	2	17.9%
DIFICLIR	11	15	4	38.1%

- EMEA: Europe, Middle East and Africa

FY14 Full Year	Forecasts	
	FY15 Full Year	Change from FY14 (%)
2,258	2,528	12.0%
241	537	122.8%
136	136	-0.6%
305	288	-5.4%
74	110	48.3%
159	157	-1.7%
130	126	-2.7%
63	64	0.8%
66	62	-6.0%
30	30	2.6%
588	603	2.7%
560	583	4.1%
207		
28	20	-27.0%
74	88	19.4%
56	53	-6.1%
13		
14		

8.Consolidated statements of financial position

Unit: B¥

	31-Mar-15	31-Dec-15	
	Amount	Amount	Change
Assets	1,793.6	1,787.8	-5.8
Non-current assets	827.6	875.7	48.1
Property, plant and equipment	202.9	202.4	-0.4
Goodwill	136.3	136.8	0.5
Other intangible assets	295.8	331.8	35.9
Trade and other receivables	15.6	22.3	6.7
Investments in associates and joint ventures	2.0	3.0	1.0
Deferred tax assets	51.2	58.7	7.5
Other financial assets	110.1	104.8	-5.3
Other non-current assets	13.7	15.9	2.2
Current assets	966.0	912.1	-53.8
Inventories	156.9	148.6	-8.3
Trade and other receivables	332.9	376.3	43.4
Income tax receivable	6.9	7.9	1.0
Other financial assets	59.9	21.7	-38.2
Other current assets	12.7	16.9	4.2
Cash and cash equivalents	396.4	340.5	-56.0
Assets held for sale	0.1	0.2	0.1

Unit: B¥

	31-Mar-15	31-Dec-15	
	Amount	Amount	Change
Equity and Liabilities	1,793.6	1,787.8	-5.8
Equity	1,317.9	1,322.3	4.4
Equity attributable to owners of the parent	1,317.9	1,322.3	4.4
Share capital	103.0	103.0	-
Capital surplus	176.8	176.9	0.0
Treasury shares	-87.0	-129.9	-42.9
Retained earnings	905.1	952.8	47.7
Other components of equity	220.0	219.5	-0.5
Liabilities	475.7	465.5	-10.2
Non-current liabilities	54.8	55.9	1.1
Trade and other payables	0.1	1.7	1.6
Deferred tax liabilities	0.0	-	-0.0
Retirement benefit liabilities	30.1	29.3	-0.8
Provisions	4.8	4.6	-0.2
Other financial liabilities	0.6	0.8	0.1
Other non-current liabilities	19.1	19.5	0.4
Current liabilities	420.9	409.6	-11.3
Trade and other payables	226.6	199.1	-27.5
Income tax payable	14.1	23.5	9.4
Provisions	85.4	96.3	10.9
Other financial liabilities	1.3	7.1	5.7
Other current liabilities	93.4	83.7	-9.8

[Three months ended December 31, 2015]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY15					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Sales	343.7	16.4%	343.8	14.9%	378.2	5.5%
Cost of sales	90.1	18.6%	78.3	-5.8%	102.1	1.7%
Ratio to Sales	26.2%		22.8%		27.0%	
Gross profit	253.6	15.7%	265.5	22.8%	276.1	7.0%
SG&A expenses	118.7	22.4%	121.1	15.5%	122.9	6.5%
Ratio to Sales	34.5%		35.2%		32.5%	
Advertising and Sales Promotion	41.6	47.7%	41.7	55.3%	41.7	9.5%
Personnel expenses	45.1	6.3%	46.2	7.7%	46.0	3.4%
Other	32.0	21.4%	33.2	-5.5%	35.2	7.2%
R&D expenses	56.0	17.5%	56.1	13.5%	53.0	3.9%
Ratio to Sales	16.3%		16.3%		14.0%	
Amortisation of intangible assets	10.9	22.8%	11.0	21.5%	11.2	11.5%
Share of profits/losses of associates and joint ventures	-0.2	-	-0.0	-	-0.2	-
Other income	1.3	-53.2%	0.3	-91.0%	0.2	-78.7%
Gain on sales of property, plant and equipment	0.1	799.6%	0.1	-92.5%	0.1	567.0%
Net foreign exchange gains	0.6	-74.3%	-	-	-	-
Other expense	7.2	-60.4%	6.9	98.4%	5.9	-74.7%
Loss on sales and disposal of property, plant and equipment	0.1	-54.9%	0.2	-52.3%	0.2	35.5%
Impairment losses	6.6	-18.7%	-	-	3.0	264.6%
Restructuring costs	-	-	-	-	-	-
Net foreign exchange losses	-	-	6.5	794.3%	1.1	-90.8%
Litigation costs	0.4	-11.9%	0.1	709.5%	1.6	-84.5%
Operating profit	61.9	22.4%	70.7	34.4%	83.0	41.8%
Ratio to Sales	18.0%		20.6%		21.9%	
Finance income	6.0	230.4%	7.3	-	0.4	-25.1%
Gain on sales of available-for-sale financial assets	5.5	540.2%	6.6	-	-	-
Finance expense	0.3	-86.9%	0.3	-56.6%	0.4	149.6%
Impairment losses for available-for-sale financial assets	0.0	-98.5%	0.1	-87.8%	0.0	-
Profit before tax	67.7	34.6%	77.8	48.4%	83.0	40.9%
Ratio to Sales	19.7%		22.6%		22.0%	
Income tax expense	23.0	59.8%	19.4	6.4%	21.4	51.1%
Profit for the period	44.6	24.4%	58.3	70.9%	61.6	37.7%
Ratio to Sales	13.0%		17.0%		16.3%	
Comprehensive income	71.8	219.0%	33.0	-49.4%	61.7	-43.9%

2. Consolidated Results (Core Basis)

Unit: B¥

		FY15					
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Sales		343.7	16.4%	343.8	14.9%	378.2	5.5%
Cost of sales		90.1	18.6%	78.3	-5.8%	102.1	1.7%
	Ratio to Sales	26.2%		22.8%		27.0%	
Gross profit		253.6	15.7%	265.5	22.8%	276.1	7.0%
SG&A expenses		118.7	22.4%	121.1	15.5%	122.9	6.5%
	Ratio to Sales	34.5%		35.2%		32.5%	
Advertising and Sales Promotion		41.6	47.7%	41.7	55.3%	41.7	9.5%
Personnel expenses		45.1	6.3%	46.2	7.7%	46.0	3.4%
Other		32.0	21.4%	33.2	-5.5%	35.2	7.2%
R&D expenses		56.0	17.5%	56.1	13.5%	53.0	3.9%
	Ratio to Sales	16.3%		16.3%		14.0%	
Amortisation of intangible assets		10.9	22.8%	11.0	21.5%	11.2	11.5%
Share of profits/losses of associates and joint ventures		-0.2	-	-0.0	-	-0.2	-
Operating profit		67.8	2.8%	77.3	45.4%	88.7	9.5%
	Ratio to Sales	19.7%		22.5%		23.5%	
Finance income		0.6	-43.2%	0.7	188.6%	0.5	-18.1%
Finance expense		0.1	-20.5%	0.2	257.6%	0.3	108.4%
Profit before Tax		68.3	2.2%	77.9	45.8%	88.9	9.1%
	Ratio to Sales	19.9%		22.6%		23.5%	
Income tax expense		23.3	13.8%	19.0	1.1%	23.4	5.6%
Profit for the period		45.0	-3.0%	58.9	70.0%	65.4	10.5%
	Ratio to Sales	13.1%		17.1%		17.3%	

3. Segment Information by Region

Unit: B¥

		FY15					
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Sales		343.7	16.4%	343.8	14.9%	378.2	5.5%
	Japan	125.6	11.3%	121.5	-2.3%	149.7	-1.1%
	Ratio to Sales	36.6%		35.3%		39.6%	
	Americas	114.8	36.9%	118.1	40.3%	115.8	15.5%
	Ratio to Sales	33.4%		34.4%		30.6%	
	EMEA	81.7	-0.8%	80.5	8.7%	89.1	2.6%
	Ratio to Sales	23.8%		23.4%		23.6%	
	Asia and Oceania	21.5	34.0%	23.7	42.4%	23.6	18.9%
	Ratio to Sales	6.3%		6.9%		6.2%	

- Calculated according to locations of sellers.

- EMEA: Europe, Middle East and Africa

4. Depreciation/Amortisation

Unit: B¥

		FY15					
		APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
		(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Depreciation (PP&E)							
	Consolidated	5.0	-4.5%	5.2	-6.2%	5.2	1.6%
Amortisation (Intangible Assets) *							
	Consolidated	12.4	21.1%	12.5	20.0%	12.7	10.5%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

5. Sales of major products

Unit: B¥

1) Sales of global products

	FY15					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	59.1	152.8%	63.3	102.4%	66.4	64.8%
US	36.2	146.7%	38.3	103.2%	38.4	48.5%
ex-US	22.8	163.2%	25.0	101.1%	28.0	94.0%
Japan	6.8	346.5%	6.3	53.3%	7.1	56.0%
Americas (ex-US)	1.0	151.6%	1.2	127.0%	1.1	13.7%
EMEA	14.6	117.3%	16.9	118.6%	19.1	120.5%
Asia and Oceania	0.4	-	0.6	937.5%	0.7	191.7%
Eligard	4.4	-12.3%	4.4	0.3%	4.8	-5.8%
EMEA	4.4	-12.9%	4.3	-0.9%	4.8	-6.7%
Asia and Oceania	0.0	349.7%	0.1	819.7%	0.1	231.7%
Vesicare	35.4	7.1%	34.3	2.3%	35.1	-6.6%
Japan	6.8	29.6%	6.5	-0.9%	7.2	-2.9%
Americas	17.1	9.9%	16.2	8.1%	15.7	-8.8%
EMEA	10.2	-7.2%	10.1	-2.7%	10.6	-7.9%
Asia and Oceania	1.2	7.6%	1.4	10.8%	1.4	4.1%
Betanis/Myrbetriq/BETMIGA	18.1	69.1%	20.0	71.7%	22.0	42.7%
Japan	4.9	81.0%	4.9	42.9%	6.0	35.8%
Americas	9.8	59.7%	11.6	93.2%	12.0	54.6%
EMEA	3.3	79.7%	3.3	52.7%	3.5	9.3%
Asia and Oceania	0.1	447.7%	0.2	396.9%	0.5	939.6%
Harnal/Omnice	14.2	3.4%	12.9	-5.6%	14.7	-5.2%
Sales by Astellas	13.3	6.2%	12.4	-5.2%	13.6	-6.6%
Japan	3.4	-11.6%	3.3	-17.1%	3.5	-12.9%
EMEA	4.7	3.7%	3.3	-27.6%	4.3	-25.0%
Asia and Oceania	5.0	25.5%	5.6	26.3%	5.7	20.2%
Bulk and Royalties	0.9	-25.4%	0.5	-13.1%	1.1	17.8%
Prograf	50.4	7.1%	54.2	12.6%	52.9	0.5%
Sales by Astellas	49.9	8.0%	53.2	12.6%	52.1	0.4%
Japan (Including Graceptor)	12.7	11.0%	12.7	3.7%	13.6	0.3%
Americas	8.4	-4.5%	9.7	19.4%	8.8	1.6%
EMEA	19.6	5.2%	20.5	4.0%	20.1	-4.6%
Advagraf	7.5	13.8%	8.3	12.9%	8.1	4.1%
Asia and Oceania	9.2	25.7%	10.3	43.7%	9.5	11.8%
Exports to third parties	0.5	-41.3%	1.0	13.1%	0.8	3.2%
Funguard/MYCAMINE	10.3	16.3%	10.8	12.0%	10.9	-4.3%
Japan	2.9	16.5%	3.1	-2.5%	3.2	-11.3%
Americas	3.3	15.5%	3.4	20.9%	3.3	-5.9%
EMEA	2.8	6.5%	2.8	14.0%	2.8	-8.2%
Asia and Oceania	1.3	49.2%	1.4	26.5%	1.5	34.4%
Protopic	4.2	-30.5%	3.7	-38.7%	4.2	-29.3%
Americas	1.0	-67.2%	0.9	-72.7%	0.9	-71.8%
EMEA	1.8	-13.4%	1.5	-17.0%	2.3	24.9%
Asia and Oceania	1.3	66.7%	1.3	46.1%	0.9	3.3%

- Sales of products in Japan are shown in a gross sales basis.

- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

	FY15					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
<Global products>						
XTANDI	6.8	346.5%	6.3	53.3%	7.1	56.0%
Vesicare	6.8	29.6%	6.5	-0.9%	7.2	-2.9%
Betanis	4.9	81.0%	4.9	42.9%	6.0	35.8%
Harnal	3.4	-11.6%	3.3	-17.1%	3.5	-12.9%
Prograf (Including Graceptor)	12.7	11.0%	12.7	3.7%	13.6	0.3%
Funguard	2.9	16.5%	3.1	-2.5%	3.2	-11.3%
<Local products in Japan>						
Micardis [Family]	24.8	6.3%	23.7	-0.3%	28.4	1.5%
Micombi	2.7	-3.0%	2.5	-7.5%	2.9	-3.8%
Micamlo	6.5	14.5%	6.2	8.1%	7.6	9.3%
Celecox	11.8	41.4%	11.6	3.0%	12.7	6.1%
Symbicort	9.0	44.2%	8.5	3.5%	11.3	7.8%
Bonoteo	3.7	39.8%	3.4	-0.9%	3.9	5.3%
Geninax	2.8	20.9%	2.0	-2.5%	3.8	0.7%
Vaccines	6.6	24.6%	7.4	1.1%	24.6	17.8%
Argamate	1.5	6.5%	1.5	2.9%	1.7	4.1%
Kiklin	0.4	23.2%	0.4	3.0%	0.4	0.8%
Gonax	0.9	26.1%	1.0	11.6%	1.0	8.9%
Cimzia	1.6	40.1%	1.6	29.9%	1.8	27.9%
Suglat	2.0	-18.2%	1.4	-	2.0	187.3%
Lipitor*	8.3	-13.1%	7.9	-18.6%	8.5	-12.6%
Myslee	4.7	-3.6%	4.6	-8.5%	5.0	-5.1%
Gaster	3.9	-17.4%	3.8	-19.8%	4.0	-14.8%
Seroquel	3.0	-13.4%	2.7	-15.3%	2.8	-17.6%
Total Rx Sales In Japanese market	122.2	12.1%	117.8	-2.3%	146.1	0.3%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015.

3) Sales of products in Americas and EMEA

Unit: B¥

	FY15					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Scan* (Americas)	20.8	25.1%	19.8	27.1%	18.2	6.4%
Lexiscan	20.8	26.2%	19.7	26.4%	18.1	6.6%
AmBisome (Americas)	2.8	47.7%	2.7	19.5%	2.7	14.1%
Tarceva	13.1	-3.2%	12.4	11.1%	11.7	-3.9%
(US)	9.7	0.5%	8.9	17.4%	8.5	5.5%
(ex-US)	3.4	-12.3%	3.5	-2.4%	3.2	-22.2%
Qutenza (EMEA)	0.5	16.3%	0.5	15.6%	0.6	7.9%
DIFICLIR (EMEA)	0.6	34.7%	0.7	37.1%	0.6	25.5%

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4) Sales in Americas and EMEA (Local currency)

Unit: M\$

Americas	FY15					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Sales	946	15.2%	966	19.3%	953	8.3%
XTANDI	307	107.8%	323	73.1%	325	36.0%
US	298	107.6%	313	72.5%	316	37.2%
Americas (ex-US)	9	111.8%	10	92.7%	9	3.7%
Tarceva	108	-18.5%	101	-5.4%	97	-8.6%
US	80	-15.4%	73	0.0%	70	0.8%
ex-US	28	-26.1%	28	-16.9%	27	-26.7%
VESicare	141	-7.5%	133	-8.0%	129	-14.1%
Myrbetriq	81	34.4%	95	64.4%	98	44.4%
Prograf	69	-19.6%	80	1.6%	73	-3.7%
Scan*	171	5.3%	162	8.1%	150	0.7%
Lexiscan	171	6.2%	161	7.5%	149	0.8%
MYCAMINE	27	-2.8%	28	2.8%	27	-12.0%
AmBisome	23	24.3%	22	1.4%	22	7.4%
CRESEMBA	2	-	5	-	7	-
Protopic	8	-72.4%	8	-76.8%	7	-73.1%

* Adenoscan + Lexiscan

Unit: M€

EMEA	FY15					
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Sales	609	3.5%	592	10.0%	670	10.2%
XTANDI	109	126.9%	125	121.9%	144	136.1%
Eligard	33	-9.1%	32	0.3%	36	0.2%
Vesicare	76	-3.1%	75	-1.4%	80	-1.0%
BETMIGA	25	87.7%	25	54.9%	26	16.7%
Omnice	42	1.8%	28	-25.2%	40	-13.4%
Sales by Astellas	35	8.2%	24	-26.9%	32	-19.6%
Capsule	18	14.3%	11	-37.0%	16	-19.9%
OCAS	17	2.4%	14	-16.7%	16	-19.4%
Bulk and Royalties	7	-22.1%	4	-13.0%	8	26.5%
Prograf	150	7.6%	158	5.9%	157	2.8%
Sales by Astellas	146	9.8%	151	5.5%	151	2.5%
Advagraf	56	18.8%	61	14.6%	61	11.8%
Exports to third parties	4	-38.8%	7	15.0%	6	11.4%
MYCAMINE	21	11.2%	20	15.4%	21	-1.6%
Protopic	14	-9.5%	11	-16.2%	17	34.1%
Qutenza	4	21.5%	3	16.9%	4	15.6%
DIFICLIR	5	40.7%	5	39.0%	5	35.0%

- EMEA: Europe, Middle East and Africa